½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹MLANA¶à¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • Íÿ¹MLANA¶à¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW19009
    • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul/200ul/25ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·


ÖÐÎÄÃû³Æ£º  Íÿ¹MLANA¶à¿Ë¡¿¹Ìå


Ó¢ÎÄÃû³Æ£º  Anti-MLANA rabbit polyclonal antibody


±ð      Ãû£º  MART1; MART-1


Ïà¹ØÀà±ð£º  Ò»¿¹


´¢      ´æ£º  Àä¶³£¨-20¡æ£©


ËÞ      Ö÷£º  Rabbit


¿¹      Ô­£º  MLANA


·´Ó¦ÖÖÊô£º  Human


±ê  ¼Ç Î  Unconjugate


¿Ë¡ÀàÐÍ£º  rabbit polyclonal


¼¼Êõ¹æ¸ñ

Background:

Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients. Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.

Applications:

ELISA, IHC

Name of antibody:

MLANA

Immunogen:

Synthetic peptide of human MLANA

Full name:

melan-A

Synonyms:

MART1; MART-1

SwissProt:

Q16655

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human esophagus cancer

IHC Recommend dilution:

40-250




¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿